• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性卵巢类癌肿瘤。

Primary ovarian carcinoid tumors.

作者信息

Davis K P, Hartmann L K, Keeney G L, Shapiro H

机构信息

Department of Gynecologic Oncology, Presbyterian St. Lukes Medical Center, Colorado 80218,USA.

出版信息

Gynecol Oncol. 1996 May;61(2):259-65. doi: 10.1006/gyno.1996.0136.

DOI:10.1006/gyno.1996.0136
PMID:8626144
Abstract

Primary ovarian carcinoid tumors were reviewed from Mayo Clinic and Colorado Tumor Registry data. A total of 17 patients with this diagnosis were identified. Histologic analysis of these carcinoid tumors revealed 9 (53%) were insular, 5 (29%) were trabecular, and 4 (26%) were strumal carcinoid with or without a mature dermoid component. There were 11 patients with stage I and 6 patients with stage III or IV disease at diagnosis. Carcinoid syndrome was found in 29% of patients. Pressure or pain with defecation was noted in 41% of cases. Recurrence of tumor occurred in 1 of 11 patients with suspected stage I disease 13 years after initial diagnosis. Overall survival was excellent in the 11 patients whose disease was confined to one ovary (100% 5-year survival), but only 1 of 6 patients survived (33% 5-year survival) if advanced stage at diagnosis. Systemic chemotherapy for advanced disease achieved a complete response in 1 patient and stable disease in another. Although rare, primary ovarian carcinoid tumors treated with surgery alone and found to be confined to the ovary can be expected to have an excellent overall outcome.

摘要

我们回顾了梅奥诊所和科罗拉多肿瘤登记处数据中的原发性卵巢类癌肿瘤。共识别出17例患有该疾病的患者。对这些类癌肿瘤的组织学分析显示,9例(53%)为岛状,5例(29%)为小梁状,4例(26%)为甲状腺肿类癌,伴有或不伴有成熟的皮样成分。诊断时,11例患者为I期,6例患者为III期或IV期疾病。29%的患者出现类癌综合征。41%的病例在排便时出现压迫感或疼痛。11例疑似I期疾病的患者中有1例在初次诊断13年后出现肿瘤复发。疾病局限于一侧卵巢的11例患者总体生存率良好(5年生存率100%),但如果诊断时处于晚期,6例患者中只有1例存活(5年生存率33%)。晚期疾病的全身化疗使1例患者达到完全缓解,另1例患者病情稳定。虽然罕见,但仅接受手术治疗且局限于卵巢的原发性卵巢类癌肿瘤预计总体预后良好。

相似文献

1
Primary ovarian carcinoid tumors.原发性卵巢类癌肿瘤。
Gynecol Oncol. 1996 May;61(2):259-65. doi: 10.1006/gyno.1996.0136.
2
The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.伴有非侵袭性种植的卵巢浆液性交界性肿瘤的复发率和总生存率与时间相关。
Am J Surg Pathol. 2006 Nov;30(11):1367-71. doi: 10.1097/01.pas.0000213294.81154.95.
3
Primary trabecular carcinoid of the ovary.卵巢原发性小梁类癌
Obstet Gynecol. 1977 Feb;49(2):202-7.
4
Recurrence and prognostic factors in borderline ovarian tumors.卵巢交界性肿瘤的复发及预后因素
Gynecol Oncol. 2005 Sep;98(3):439-45. doi: 10.1016/j.ygyno.2005.05.033.
5
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.手术细胞减灭术对IV期上皮性卵巢癌生存的影响。
Gynecol Oncol. 1999 Mar;72(3):278-87. doi: 10.1006/gyno.1998.5145.
6
Relapse and survival in early-stage ovarian cancer.早期卵巢癌的复发与生存
Arch Gynecol Obstet. 2009 Jul;280(1):71-7. doi: 10.1007/s00404-008-0877-z. Epub 2008 Dec 18.
7
Therapy of advanced ovarian juvenile granulosa cell tumors.晚期卵巢幼年型颗粒细胞瘤的治疗
Klin Padiatr. 2002 Jul-Aug;214(4):173-8. doi: 10.1055/s-2002-33183.
8
Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.卵巢交界性肿瘤保守性手术后的长期结局:一项基于大人群的研究。
Gynecol Oncol. 2006 Dec;103(3):841-7. doi: 10.1016/j.ygyno.2006.05.014. Epub 2006 Jun 21.
9
Secondary malignancies in ovarian dermoid cyst.卵巢皮样囊肿中的继发性恶性肿瘤。
Saudi Med J. 2009 Apr;30(4):524-8.
10
Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.卵巢非小细胞神经内分泌癌:11例临床病理及免疫组化研究
Am J Surg Pathol. 2007 May;31(5):774-82. doi: 10.1097/01.pas.0000213422.53750.d1.

引用本文的文献

1
Hypertension and Carcinoid Heart Disease as Initial Manifestations of Ovarian Carcinoid Tumor.高血压和类癌性心脏病作为卵巢类癌肿瘤的初始表现
JCEM Case Rep. 2025 Apr 17;3(5):luaf073. doi: 10.1210/jcemcr/luaf073. eCollection 2025 May.
2
Carcinoid Heart Disease Associated with Primary Ovarian Carcinoid Tumor: A Rare Presentation.类癌性心脏病与原发性卵巢类癌肿瘤相关:一种罕见的表现。
Heart Views. 2024 Apr-Jun;25(2):106-109. doi: 10.4103/heartviews.heartviews_104_23. Epub 2024 Oct 10.
3
Incidental Diagnosis of a Primary Pure "Mixed" Ovarian Carcinoid: Clinicopathological Report and Concise Review of the Recent Series.
原发性纯“混合性”卵巢类癌的偶然诊断:临床病理报告及近期病例系列的简要综述
Case Rep Obstet Gynecol. 2024 Mar 27;2024:5890300. doi: 10.1155/2024/5890300. eCollection 2024.
4
Clinical characteristics and survival outcomes in patients with primary ovarian carcinoid: A historical cohort study.原发性卵巢类癌的临床特征和生存结局:一项历史性队列研究。
Acta Obstet Gynecol Scand. 2023 Jul;102(7):935-941. doi: 10.1111/aogs.14578. Epub 2023 Apr 14.
5
Neuroendocrine Neoplasms of the Gastrointestinal Tract versus Neuroendocrine Neoplasms of the Gynaecological Tract-Comparison of the Risk Factors and Non-Surgical Treatment Efficacy.胃肠道神经内分泌肿瘤与妇科生殖道神经内分泌肿瘤——危险因素和非手术治疗疗效比较。
Int J Mol Sci. 2023 Apr 6;24(7):6853. doi: 10.3390/ijms24076853.
6
Primary Ovarian Neuroendocrine Carcinoid Tumor Arising in a Mature Cystic Teratoma.成熟性囊性畸胎瘤中发生的原发性卵巢神经内分泌类癌肿瘤
Case Rep Oncol. 2023 Mar 15;16(1):157-161. doi: 10.1159/000529838. eCollection 2023 Jan-Dec.
7
Ovarian strumal carcinoid: a case report.卵巢支持细胞瘤性类癌:一例报告。
Fukushima J Med Sci. 2023 Apr 5;69(1):51-55. doi: 10.5387/fms.2022-22. Epub 2023 Mar 4.
8
Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid.卵巢甲状腺类癌患者的临床特征和生存结局。
BMC Cancer. 2022 Oct 24;22(1):1090. doi: 10.1186/s12885-022-10167-5.
9
A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease.原发性胰岛卵巢类癌瘤伴高雄激素血症及类癌心脏病 1 例报告
Am J Case Rep. 2022 Oct 1;23:e937403. doi: 10.12659/AJCR.937403.
10
Carcinoid ovary with synchronous carcinoid tumour of the appendix: report of a rare occurrence with review of literature.卵巢类癌伴阑尾类癌同步肿瘤:罕见病例报告并文献复习
BMJ Case Rep. 2022 Jun 24;15(6):e248869. doi: 10.1136/bcr-2022-248869.